All ChristianaCare’s Gene Editing Institute articles
-
NewsCRISPR disruption of NRF2 re-sensitises tumours to chemo
Researchers have shown that using CRISPR to disable the NRF2 gene can restore chemotherapy sensitivity and slow tumour growth.